Practice-changing results reported for Revolution Medicines pancreatic cancer drug Daraxonrasib nearly doubled survival time compared to standard chemotherapy

https://www.statnews.com/2026/05/31/pancreatic-cancer-daraxonrasib-revolution-medicines-results-asco-2026/ By Adam FeuersteinMay 31, 2026 Senior Writer, Biotech